title: Case report: Kasabach-Merritt syndrome: a review of the therapeutic options and a case report of successful treatment with radiotherapy and interferon alpha.
abstract: We describe the successful treatment of a neonate with Kasabach-Merritt syndrome who received local irradiation and interferon alpha therapy after failure of corticosteroid treatment. A male neonate, born after an uneventful pregnancy, had a huge haemangioma involving the upper right cervical region as well as severe thrombocytopenia. He was treated with corticosteroids, interferon alpha and radiotherapy. Prednisolone therapy (5 mg kg(-1) day(-1)) was started at 41 days of age. No therapeutic effect was observed after 2 weeks. At this time the tumour size had increased dramatically, platelet counts had decreased progressively and coagulation abnormalities had developed. Because corticosteroid therapy had been ineffective and the child was in a life-threatening condition, irradiation was delivered up to a total dose of 9.5 Gy in five fractions. Simultaneously, prednisolone therapy was slowly decreased and interferon alpha therapy (3 million U m(-2) day(-1)) was started and continued for 6 weeks. After irradiation with 9.5 Gy and beginning interferon alpha therapy, the tumour decreased in size and coagulation parameters normalized within 4 weeks. 6 months later, platelet counts and coagulation parameters were still normal. The tumour had further decreased in size. No acute severe side effects were observed. Radiation therapy combined with interferon alpha treatment is an alternative treatment modality when high dose corticoid steroid therapy has been ineffective in patients with Kasabach-Merritt syndrome, despite the risks of growth delay and secondary malignancy. In children showing no response to corticosteroids, radiotherapy and/or interferon alpha should be considered in Kasabach-Merritt syndrome.
authors.affiliation: Departments of Radiotherapy and Pediatrics, University Hospital Muenster, Albert-Schweitzer-Strasse 33, D-48149 Muenster, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Hesselmann
authors.forename: O
authors.initials: O
authors.lastname: Micke
authors.forename: T
authors.initials: T
authors.lastname: Marquardt
authors.forename: S
authors.initials: S
authors.lastname: Baas
authors.forename: J H
authors.initials: JH
authors.lastname: Bramswig
authors.forename: E
authors.initials: E
authors.lastname: Harms
authors.forename: N
authors.initials: N
authors.lastname: Willich
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy / Q000532:radiotherapy; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D006391:Hemangioma / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D007231:Infant, Newborn; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D013577:Syndrome; D013921:Thrombocytopenia / Q000188:drug therapy / Q000532:radiotherapy
chemical_list: D000970:Antineoplastic Agents; D016898:Interferon-alpha